Dr. Thornton is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
601 Elmwood Ave
Rochester, NY 14642Phone+1 585-275-2542Fax+1 585-273-1255
Education & Training
University of RochesterResidency, Neurology, 1989 - 1991
Oregon Health & Science University (OHSU Health)Residency, Neurology, 1982 - 1985
UCLA-VA Greater Los AngelesInternship, Internal Medicine, 1981 - 1982
University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1981
Certifications & Licensure
OR State Medical License 1983 - Present
NY State Medical License 1989 - 2025- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry Start of enrollment: 2000 Sep 01
- Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1 Start of enrollment: 2011 Jun 01
- Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Start of enrollment: 2019 Jan 01
Publications & Presentations
PubMed
- 5 citationsVerapamil mitigates chloride and calcium bi-channelopathy in a myotonic dystrophy mouse model.Lily A Cisco, Matthew T Sipple, Katherine M Edwards, Charles A Thornton, John D Lueck
The Journal of Clinical Investigation. 2024-01-02 - Combinatorial chloride and calcium channelopathy in myotonic dystrophy.Lily A Cisco, Matthew T Sipple, Katherine M Edwards, Charles A Thornton, John D Lueck
Biorxiv. 2023-06-01 - 12 citationsAntisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial.Charles A Thornton, Richard Thomas Moxley 3rd, Katy Eichinger, Chad Heatwole, Laurence Mignon
The Lancet. Neurology. 2023-03-01
Press Mentions
Triplet Therapeutics Announces Participation in Natural History Study of Myotonic Dystrophy Type 1August 18th, 2020
Grant Marks Two Decades of NIH Support for Muscular Dystrophy ResearchFebruary 25th, 2019- Finding a Treatment for Postoperative Cognitive DysfunctionOctober 4th, 2017
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
